Cover Image
市場調查報告書

創傷後壓力症候群(PTSD):開發平台分析

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 213134
出版日期 內容資訊 英文 137 Pages
訂單完成後即時交付
價格
Back to Top
創傷後壓力症候群(PTSD):開發平台分析 Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2017
出版日期: 2017年07月11日 內容資訊: 英文 137 Pages
簡介

創傷後壓力症候群(PTSD)是指遭遇或目擊可怕的事情後引起的精神衛生狀態。症狀不僅有不斷閃回事件畫面、惡夢及嚴重不安,還包括了無法控制自己對創傷回億的思考。治療有給予抗憂鬱藥,抗焦慮·意識療法等。

本報告提供全球治療創傷後壓力症候群(PTSD)用之開發中產品的開發情形相關分析,提供您產品開發·上市的最新趨勢,臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

創傷後壓力症候群(PTSD)概要

治療藥的開發

  • 創傷後壓力症候群(PTSD)開發中產品:概要
  • 創傷後壓力症候群(PTSD)開發中產品:比較分析

創傷後壓力症候群(PTSD):各企業正在開發的治療藥

創傷後壓力症候群(PTSD):大學/研究機關研究中的治療藥

創傷後壓力症候群(PTSD):開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

創傷後壓力症候群(PTSD):開發中的產品的一覽(各企業)

創傷後壓力症候群(PTSD):研究中的產品的一覽(大學/研究機關別)

創傷後壓力症候群(PTSD)的開發企業

  • Addex Therapeutics Ltd
  • Amorsa Therapeutics Inc.
  • Azevan Pharmaceuticals, Inc.
  • 分析的背景 Pharmaceutical Partners, Inc.
  • Eli Lilly and Company
  • HolsboerMaschmeyer NeuroChemie GmbH
  • Humanetics Corporation
  • Intra-Cellular Therapies, Inc.
  • INVENT Pharmaceuticals, Inc.
  • Marinus Pharmaceuticals, Inc.
  • Neuralstem, Inc.
  • NeuroNascent, Inc.
  • Omeros Corporation
  • 大塚集團
  • Polleo Pharma Limited
  • Synchroneuron Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • Turing Pharmaceuticals AG
  • Vanda Pharmaceuticals Inc.

創傷後壓力症候群(PTSD):治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • acamprosate calcium SR
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • ADX-71743
  • AM-3506
  • brexpiprazole
  • CPP-115
  • Drug for Post-Traumatic Stress Disorders
  • Drugs to Inhibit FAAH for CNS Disorders
  • Drugs to Modulate NPSR for Anxiety Disorder
  • ganaxolone
  • HL-9001
  • IC-87201
  • iloperidone
  • INV-170
  • ITI-007
  • ketamine hydrochloride
  • NNI-351
  • NSI-189
  • Rycal
  • S-107
  • Small Molecule to Target GPR151 for CNS Diseases
  • Small Molecule to Target GPR83 for CNS and Immunological Disorders
  • Small Molecules for Post-Traumatic Stress Disorder
  • Small Molecules for Post-Traumatic Stress Disorder
  • Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders
  • Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders
  • Small Molecules to Antagonize mGluR7 for Post-Traumatic Stress Disorders and Acute Stress Disorder
  • Small Molecules to Antagonize TLR-4 for CNS Disorders
  • SRX-246
  • TNX-102
  • Vaccine for CNS Disorders
  • vigabatrin
  • ZL-006

創傷後壓力症候群(PTSD):開發中產品的最新趨勢

創傷後壓力症候群(PTSD):開發暫停的產品

創傷後壓力症候群(PTSD):開發中止的產品

創傷後壓力症候群(PTSD)相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9512IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2017, provides an overview of the Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline landscape.

Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 3, 18 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 7 and 1 molecules, respectively.

Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Post-Traumatic Stress Disorder (PTSD) - Overview
    • Post-Traumatic Stress Disorder (PTSD) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Amorsa Therapeutics Inc
    • Azevan Pharmaceuticals Inc
    • Bionomics Ltd
    • Catalyst Pharmaceuticals Inc
    • Cerecor Inc
    • Chronos Therapeutics Ltd
    • Corcept Therapeutics Inc
    • Eli Lilly and Company
    • Embera NeuroTherapeutics Inc
    • Immodulon Therapeutics Ltd
    • Intra-Cellular Therapies Inc
    • Marinus Pharmaceuticals Inc
    • Neuralstem Inc
    • NeuroNascent Inc
    • Omeros Corp
    • Otsuka Holdings Co Ltd
    • Pragma Therapeutics SAS
    • Synchroneuron Inc
    • Tonix Pharmaceuticals Holding Corp
  • Post-Traumatic Stress Disorder (PTSD) - Drug Profiles
    • (metyrapone + oxazepam) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • acamprosate calcium SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-71743 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-3506 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNC-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brexpiprazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CERC-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CPP-115 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTDP-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-473 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ganaxolone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IC-87201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMM-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INV-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KDAC-0001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lumateperone tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • midomafetamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • modafinil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NNI-351 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NSI-189 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PGT-117 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Rycal - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize EP1 for Post-Traumatic Stress Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Nociceptin Receptor for Post Traumatic Stress Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Glucocorticoid Receptor II for Post Traumatic Stress Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target NMDA Receptor for Post-Traumatic Stress Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRX-246 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Antagonize EPHA4 for Post-Traumatic Stress Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Target NPSR for Anxiety Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TNX-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TNX-601 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZL-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Post-Traumatic Stress Disorder (PTSD) - Dormant Projects
  • Post-Traumatic Stress Disorder (PTSD) - Discontinued Products
  • Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 16, 2017: Tonix Pharmaceuticals to Present at the 2017 BIO International Convention
      • Jun 15, 2017: Bionomics Invited to PTSD State of the Science Summit to Present Key BNC210 Data
      • Jun 15, 2017: Tonix Pharmaceuticals Participated in the Pathophysiology of Posttraumatic Stress Disorder: Rethinking Drug Targets Summit Sponsored by U.S. Department of Defense
      • Jun 12, 2017: Tonix Pharmaceuticals to Present an Update of FDA Designated Breakthrough Therapy-TNX-102 SL for PTSD at the 2017 Marcum MicroCap Conference
      • May 30, 2017: Tonix Pharmaceuticals Presented Retrospective Analyses of Treatment Response and Remission to TNX-102 SL in a Phase 2 Military-Related PTSD Study
      • May 24, 2017: Tonix Pharmaceuticals to Present Additional Clinical Results of Military-Related PTSD Study at the 2017 American Society of Clinical Psychopharmacology Annual Meeting
      • May 22, 2017: Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD
      • May 20, 2017: Tonix Pharmaceuticals to Present PTSD Clinical Data at the Society of Biological Psychiatry 72nd Annual Scientific Convention
      • May 02, 2017: Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-102 SL Composition and Formulation: Designed for Transmucosal Absorption and Bedtime Daily Use
      • Apr 11, 2017: Tonix Pharmaceuticals Reports Results from U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting on TNX-102 SL for Posttraumatic Stress Disorder
      • Mar 29, 2017: Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at The MicroCap Conference
      • Mar 28, 2017: Tonix Pharmaceuticals Enrolls First Participant in Military-Related PTSD Phase 3 Trial of FDA Breakthrough Therapy-Designated TNX-102 SL
      • Mar 15, 2017: Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program at Oppenheimer's 27th Annual Healthcare Conference
      • Mar 14, 2017: Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent Covering Composition and Manufacture of TNX-102 SL
      • Mar 07, 2017: Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the 29th Annual ROTH Conference
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals Inc, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bionomics Ltd, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceuticals Inc, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Cerecor Inc, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Chronos Therapeutics Ltd, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Corcept Therapeutics Inc, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Company, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Embera NeuroTherapeutics Inc, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Immodulon Therapeutics Ltd, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Intra-Cellular Therapies Inc, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Marinus Pharmaceuticals Inc, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neuralstem Inc, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent Inc, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corp, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co Ltd, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Pragma Therapeutics SAS, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Synchroneuron Inc, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H2 2017
  • Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top